Ellie Eunkyung Im, Chief Medical Officer of Crescent Biopharma, Inc. (NASDAQ:CBIO), filed a Form 4 on September 18, 2026, reporting the automatic sale of 623 ordinary shares on September 16, 2026, to satisfy tax withholding obligations tied to vesting restricted stock units.

Key Highlights

  • Shares sold: 623 ordinary shares were disposed of on September 16, 2026, with transaction code "S."
  • Weighted average price: $17.9 per share, with individual transactions ranging from $17.10 to $19.17, inclusive.
  • Purpose: Sales were made solely to cover tax withholding obligations in connection with the settlement of restricted stock units granted on December 15, 2025.
  • Rule 10b5-1 plan: The sales were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026.
  • Remaining ownership: Following the transaction, Im directly beneficially owns 21,446 ordinary shares.

Crescent Biopharma CMO Reports Automatic RSU Tax-Withholding Sale

According to the filing, Ellie Eunkyung Im, serving as Chief Medical Officer of Crescent Biopharma, Inc., disposed of 623 ordinary shares on September 16, 2026. The filing indicates the sale was automatic, executed under a Rule 10b5-1 instruction Im adopted on February 25, 2026, "solely with the intent to cover taxes in connection with the vesting of the restricted stock units."

The filing discloses that the restricted stock units underlying these shares were originally granted to Im on December 15, 2025. The reported price of $17.9 per share is described as a weighted average, with the actual transactions occurring at prices ranging from $17.10 to $19.17, inclusive, across multiple transactions. The filing notes that Im "undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."

Following the reported disposition, Im directly holds 21,446 ordinary shares, according to the filing. The Form 4 was signed by Barbara Bispham Hale as attorney-in-fact for Ellie Im and submitted on September 18, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing reports a single disposition of 623 ordinary shares by Crescent Biopharma's Chief Medical Officer on September 16, 2026, at a weighted average price of $17.9, executed automatically under a Rule 10b5-1 plan to cover RSU-related tax obligations, leaving Im with 21,446 directly held shares.